Nuvation Bio Inc. Operating Expenses
Nuvation Bio Inc. (NUVB) reported Operating Expenses of $82.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- Nuvation Bio Inc. operating expenses for the quarter ending 2026-06-30 was $82.72M, a 20.90% increase year-over-year.
- Nuvation Bio Inc. operating expenses for the quarter ending 2026-03-31 was $79.35M, a 27.80% increase year-over-year.
- Nuvation Bio Inc. operating expenses for the quarter ending 2025-12-31 was $83.92M, a 34.24% increase year-over-year.
- Nuvation Bio Inc. operating expenses for the quarter ending 2025-09-30 was $66.20M, a 39.93% increase year-over-year.
- Nuvation Bio Inc. operating expenses for fiscal 2025 was $275.97M, a 54.04% decline from fiscal 2024.
- Nuvation Bio Inc. operating expenses for fiscal 2024 was $600.50M, a 501.57% increase from fiscal 2023.
- Nuvation Bio Inc. operating expenses for fiscal 2023 was $99.82M, a 16.63% decline from fiscal 2022.
- Nuvation Bio Inc. operating expenses for fiscal 2022 was $119.73M, a 28.31% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $82.72M 10-Q · filed 2026-08-06 | $162.07M 10-Q · filed 2026-08-06 | $245.99M derived: sum of 3 quarters · filed 2026-08-06 | $312.20M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $79.35M 10-Q · filed 2026-05-04 | $163.27M derived: sum of 2 quarters · filed 2026-05-04 | $229.47M derived: sum of 3 quarters · filed 2026-05-04 | $297.89M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | $83.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $150.13M derived: sum of 2 quarters · filed 2026-03-02 | $218.55M derived: sum of 3 quarters · filed 2026-08-06 | $275.97M 10-K · filed 2026-03-02 | |||
| 2025-09-30 | $66.20M 10-Q · filed 2025-11-03 | $134.63M derived: sum of 2 quarters · filed 2026-08-06 | $192.04M 10-Q · filed 2025-11-03 | $259.23M derived: sum of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | $68.42M 10-Q · filed 2026-08-06 | $65.85M 10-Q · filed 2025-08-07 | $130.51M 10-Q · filed 2026-08-06 | $125.84M 10-Q · filed 2025-08-07 | $193.03M derived: sum of 3 quarters · filed 2026-08-06 | $240.34M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $62.09M 10-Q · filed 2026-05-04 | $59.99M 10-Q · filed 2025-05-07 | $124.60M derived: sum of 2 quarters · filed 2026-05-04 | $171.92M derived: sum of 3 quarters · filed 2026-05-04 | $642.39M derived: sum of 4 quarters · filed 2026-05-04 | ||
| 2024-12-31 | $62.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $109.83M derived: sum of 2 quarters · filed 2026-03-02 | $580.30M derived: sum of 3 quarters · filed 2026-03-02 | $600.50M 10-K · filed 2026-03-02 | $593.42M 10-K · filed 2025-03-06 | ||
| 2024-09-30 | $47.31M 10-Q · filed 2025-11-03 | $517.79M derived: sum of 2 quarters · filed 2025-11-03 | $537.99M 10-Q · filed 2025-11-03 | $558.82M derived: sum of 4 quarters · filed 2025-11-03 | |||
| 2024-06-30 | $470.47M 10-Q · filed 2025-08-07 | $490.67M 10-Q · filed 2025-08-07 | $511.50M derived: sum of 3 quarters · filed 2025-08-07 | $537.84M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $20.20M 10-Q · filed 2025-05-07 | $41.03M derived: sum of 2 quarters · filed 2025-05-07 | $67.37M derived: sum of 3 quarters · filed 2025-05-07 | $93.50M derived: sum of 4 quarters · filed 2025-05-07 | |||
| 2023-12-31 | $20.83M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $47.17M derived: sum of 2 quarters · filed 2025-03-06 | $73.30M derived: sum of 3 quarters · filed 2025-03-06 | $99.82M 10-K · filed 2025-03-06 | |||
| 2023-09-30 | $26.34M 10-Q · filed 2024-11-06 | $52.47M derived: sum of 2 quarters · filed 2024-11-06 | $78.99M 10-Q · filed 2024-11-06 | $103.33M derived: sum of 4 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $26.13M 10-Q · filed 2024-08-05 | $52.65M 10-Q · filed 2023-08-03 | $76.99M derived: sum of 3 quarters · filed 2024-08-05 | $106.33M derived: sum of 4 quarters · filed 2024-08-05 | |||
| 2023-03-31 | $26.52M 10-Q · filed 2024-05-14 | $50.86M derived: sum of 2 quarters · filed 2024-05-14 | $80.19M derived: sum of 3 quarters · filed 2024-05-14 | $118.06M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $24.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $53.67M derived: sum of 2 quarters · filed 2024-02-29 | $91.54M derived: sum of 3 quarters · filed 2024-02-29 | $119.73M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $29.34M 10-Q · filed 2023-11-02 | $67.21M derived: sum of 2 quarters · filed 2023-11-02 | $95.40M 10-Q · filed 2023-11-02 | $125.01M derived: sum of 4 quarters · filed 2023-11-02 | |||
| 2022-06-30 | $37.87M 10-Q · filed 2023-08-03 | $66.06M 10-Q · filed 2023-08-03 | $95.67M derived: sum of 3 quarters · filed 2023-08-03 | $118.46M derived: sum of 4 quarters · filed 2023-08-03 | |||
| 2022-03-31 | $28.19M 10-Q · filed 2023-05-04 | $57.80M derived: sum of 2 quarters · filed 2023-05-04 | $80.59M derived: sum of 3 quarters · filed 2023-05-04 | $101.03M derived: sum of 4 quarters · filed 2023-05-04 | |||
| 2021-12-31 | $29.61M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $52.40M derived: sum of 2 quarters · filed 2023-03-15 | $72.83M derived: sum of 3 quarters · filed 2023-03-15 | $93.32M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $22.79M 10-Q · filed 2022-11-03 | $43.23M derived: sum of 2 quarters · filed 2022-11-03 | $63.71M 10-Q · filed 2022-11-03 | $77.48M derived: sum of 4 quarters · filed 2022-11-03 | |||
| 2021-06-30 | $20.43M 10-Q · filed 2022-08-04 | $40.92M 10-Q · filed 2022-08-04 | $54.69M derived: sum of 3 quarters · filed 2022-08-04 | $66.23M derived: sum of 4 quarters · filed 2022-08-04 | |||
| 2021-03-31 | $20.48M 10-Q · filed 2022-05-09 | $34.25M derived: sum of 2 quarters · filed 2022-05-09 | $45.80M derived: sum of 3 quarters · filed 2022-05-09 | $54.81M derived: sum of 4 quarters · filed 2022-05-09 | |||
| 2020-12-31 | $13.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $25.31M derived: sum of 2 quarters · filed 2022-02-28 | $34.33M derived: sum of 3 quarters · filed 2022-02-28 | $43.55M 10-K · filed 2022-02-28 | |||
| 2020-09-30 | $11.55M 10-Q · filed 2021-11-10 | $20.56M derived: sum of 2 quarters · filed 2021-11-10 | $29.78M 10-Q · filed 2021-11-10 | ||||
| 2020-06-30 | $9.02M 10-Q · filed 2021-08-12 | $18.24M 10-Q · filed 2021-08-12 | |||||
| 2020-03-31 | $9.22M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |